New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Revolutionizing Atopic Dermatitis

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Sean Pokorney, MD, MBA | Image Credit: DukeHealth

A recent secondary analysis of a randomized clinical trial has indicated the success of self-administered etripamil in treating 

paroxysmal supraventricular tachycardia (PSVT)

PSVT has long been treated through oral prophylaxis with various antiarrhythmic drugs. However, in taking these drugs and drug combinations, patients run the risk of adverse effects. Additionally, despite optimal administration of and compliance with treatment, relapses are not uncommon.

“Self-administered etripamil was nearly twice as likely as placebo to terminate a PSVT episode within 30 minutes,” wrote Sean Pokorney, MD, MBA, department of medicine, Duke University School of Medicine, and colleagues. “Self-administered, outpatient-based treatment for PSVT could contribute to reduced emergency department (ED) visits and cost and complexity of care.”

Investigators examined data from the NODE-301 Phase 3 trial, which investigated the efficacy and safety of etripamil nasal spray for treating PSVT. After receiving a test dose, participants were randomized 2:1 to receive either etripamil 70 mg or placebo. When symptoms of PSVT developed, patients applied a cardiac monitor and attempted a vagal maneuver. If symptoms continued, patients would self-administer blinded treatment.

Although NODE-301 failed to reach its primary 5-hour efficacy endpoint, etripamil was deemed safe and well-tolerated based on the data collected. In the second part, RAPID, patients were administered a repeat dose of etripamil 70 mg 10 minutes after the first dose if symptoms persisted. Patients were advised to seek medical care if they did not resolve within 30 minutes after study drug administration.

Investigators examining both trials collected data on patients seeking emergency care within 24 hours of treatment, and X2 tests were performed on pooled data to determine statistical significance between the placebo and etripamil cohorts. Two-sided 

 <.05 indicated statistical significance.

In total, 370 patients attempted vagal maneuvers during PSVT episodes before drug administration. Among these, only 17 (4.6%) had PSVT termination. The pooled cohort comprised 340 patients with a mean age of 54.7 years, and 69.7% were female. Overall, 206 patients received etripamil and 134 received placebo.

PSVT termination was confirmed in 119 patients (57.8%) within 30 minutes of using etripamil compared with 43 (32.1%) using placebo (

 <.001). Further analysis showed 34 patients (25.4%) in the placebo cohort and 30 (14.6%) in the etripamil cohort received additional intervention in the form of oral or intravenous medications (

 = .01). Only 28 of 206 (13.6%) etripamil recipients required an ED visit for ongoing PSVT symptoms, versus 30 of 134 placebo recipients (22.4%). This demonstrated an absolute risk reduction of 8.8% and a relative risk (RR) reduction of 39% (RR, 0.61; 95% CI, .38-.97, 

Given these data, Pokorney and colleagues indicated that etripamil has a substantially better rate of PSVT treatment than either vagal maneuvers or oral medications. Widespread acceptance of self-administered etripamil treatment could lead to reduced financial burden on patients and fewer ED visits.

“Limitations included pooling the studies for statistical power,” Pokorney and colleagues wrote. “Future analyses of etripamil’s implications for ED visits would broaden the applicability of results.”

Pokorney SD, Camm AJ, Dorian P, et al. Self-administered etripamil and emergency department visits in supraventricular tachycardia. 

. Published online April 9, 2025. doi:10.1001/jamacardio.2025.0417

Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. 

Journal of the American College of Cardiology

. 2001;37(2):548-553. doi:10.1016/s0735-1097(00)01128-1

Stambler BS, Plat F, Sager PT, et al. First randomized, Multicenter, placebo-controlled study of self-administered intranasal etripamil for acute conversion of spontaneous paroxysmal supraventricular tachycardia (node-301). 

Circulation: Arrhythmia and Electrophysiology

. 2022;15(12). doi:10.1161/circep.122.010915

Articles

A secondary analysis of a clinical trial has shown that self-administered etripamil is effective in treating paroxysmal supraventricular tachycardia (PSVT) outside the hospital. Etripamil was nearly twice as effective as placebo in terminating PSVT episodes within 30 minutes, potentially reducing emergency department visits and healthcare costs. The NODE-301 trial demonstrated etripamil's safety and tolerability, although it did not meet its primary endpoint. The study highlighted the potential of etripamil to outperform traditional treatments like vagal maneuvers and oral medications, despite limitations in statistical power due to pooled data.

Data suggest that etripamil may be more effective than vagal maneuvers and oral prophylaxis, minimizing emergency department visits.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Arrhythmia

Dyslipidemia

Self-Administered Etripamil Nasal Spray Treats Tachycardia, Study Suggests

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

New research has revealed that patients with 

 syndrome (FMS) had higher rates of astigmatism, meibomian gland dysfunction (MGD), and dry eye disease (DED) than those without, emphasizing the importance of routine anterior segment assessments in this population.

“In recent years, there has been a growing interest in the ophthalmologic involvement of FMS as research has begun to reveal ocular manifestations in these patients. Among the most common complaints are dry eye symptoms, photophobia, and vision problems, all of which are hypothesized to be associated with immunological alterations and autonomic nervous system dysfunctions… Patients with chronic pain syndrome have dry eye symptoms, even when their clinical grade of ocular surface illness is comparable to or less severe than that of dry eye patients without chronic pain. Ocular manifestations may contribute to the overall burden of the disease; nevertheless, the comprehensive level of ocular involvement in FMS is still not completely understood,” lead investigator Duygu Topaktaş Emekli, Department of Ophthalmology, Adana City Training and Research Hospital, Adana, Turkey, and colleagues wrote.

In this cross-sectional and comparative analysis, Emekli and colleagues collected data at a tertiary care education and research hospital from August 2024 to November 2024. They evaluated participants’ central corneal thickness, uncorrected and best-corrected visual acuities, refraction parameters, intraocular pressure, MGD, and DED.

The investigators did not find any significant differences in visual acuity, spherical equivalent, intraocular pressure, or central corneal thickness between FMS and healthy controls (all 

 >.05). They did find differences in astigmatism, MGD, and DED. Specifically, the FMS group had median astigmatism of − 0.50 (range, -8.25–0) in the right eye (diopter) compared with − 0.12 (range, -1.75–0.50) in the control group (

= .012); and − 0.50 (range, -2–1.50) in the left eye compared with and 0 (range, -1.75–0.75) in the control group.

Furthermore, 36.6% (n = 26) of the FMS group had MGD and 60.6% (n = 43) had DED, compared with 4.3% (n = 3; 

<.001) in the control group, respectively.

“These data show that FMS may predispose to these issues. The increased frequency of dry eye disease and meibomian gland dysfunction in FMS patients underscores the necessity for regular ocular assessments in this patient group. Future research should prioritize longitudinal studies with larger sample sizes to ascertain causal links and investigate the temporal dynamics of ocular alterations in FMS. Furthermore, assessments of drug effects, autonomic function, and psychiatric abnormalities (such as depression, anxiety, and sleep issues) are crucial for clarifying the underlying mechanisms and pinpointing prospective treatment strategies,” Emekli and colleagues concluded.

Emekli and colleagues previously conducted a similar study evaluating ophthalmic vascular and neuroretinal alterations in people with FMS and found only slight differences in retinal parafoveal thickness and foveal density in FMS patients, with no substantial vascular or neurodegenerative alterations compared to healthy controls.

Emekli DT, Sahutoglu E, Öztürk GY, Kocyigit BF. Anterior segment alterations in fibromyalgia syndrome: a cross-sectional study on dry eye disease, meibomian gland dysfunction, and astigmatism. 

2025;45(5):120. Published 2025 Apr 25. doi:10.1007/s00296-025-05872-w

Öztürk GY, Emekli DT, Sahutoglu E, Kocyigit BF. Evaluation of ophthalmic vascular and neuroretinal alterations in fibromyalgia syndrome: a cross-sectional comparative study. 

 2024;44(9):1757-1765. doi:10.1007/s00296-024-05662-w

Recent research indicates that fibromyalgia syndrome (FMS) patients exhibit higher rates of astigmatism, meibomian gland dysfunction (MGD), and dry eye disease (DED) compared to healthy individuals. This underscores the need for routine ocular assessments in FMS patients. The study found no significant differences in visual acuity or intraocular pressure between FMS patients and controls, but highlighted the prevalence of MGD and DED in the FMS group. Future research should focus on longitudinal studies to explore causal relationships and the impact of various factors on ocular health in FMS.

New findings highlight the link between fibromyalgia syndrome and increased rates of astigmatism, dry eye disease, and meibomian gland dysfunction.

Fibromyalgia

On the HCPLive fibromyalgia page, resources on the topics of medical news and expert insight into fibrositis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on fibromyalgia, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

People With Fibromyalgia Have Higher Rates of Astigmatism, Dry Eye, MGD

Jay Pepose, MD, PhD, is the Founder and active Medical Director of the Pepose Vision Institute.

Phentolamine Ophthalmic Solution for Low Mesopic Vision, With Jay Pepose, MD, PhD

American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

, Jay Pepose, MD, PhD, founder and active medical director of the Pepose Vision Institute, presented results from two Phase 3 randomized, placebo-controlled trials evaluating 0.75% phentolamine ophthalmic solution in patients experiencing night vision disturbances after 

These disturbances, including glare, halos, and starbursts, often stem from enlarged pupils unmasking corneal irregularities under low-light conditions—a longstanding unmet clinical need with no approved treatments.

“We see that this is an unmet need, and we're trying to develop what could be the first drug for the treatment of patients with reduced mesopic vision and photic phenomenon following keratoac surgery,” Pepose told 

In the first Phase 3 trial (LYNX-1), 143 participants—including 25 post-keratorefractive surgery—were randomized to phentolamine ophthalmic solution or placebo for 14 nights. The primary endpoint was a ≥3-line improvement in mesopic low-contrast visual acuity (mLCVA). By Day 8, 13% of phentolamine-treated patients achieved this improvement, compared with 3% in the placebo group (

Further analysis showed this improvement in phentolamine-treated participants grew to 21% versus 3% (

 <0.01) by Day 15. Among keratorefractive patients, the trend was more pronounced: 29% vs 9% at Day 8, and 21% vs 0% at Day 15.

Pepose emphasized phentolamine ophthalmic solution’s unique mechanism: it moderately constricts pupils by blocking α1 receptors on the dilator muscle, without acting on the ciliary body—avoiding the risks of retinal detachment associated with traditional miotics like pilocarpine.

A second Phase 3 trial (LYNX-2), focused exclusively on post-keratorefractive patients, has completed enrollment of 200 participants. The study, conducted under conditions of a Special Protocol Assessment (SPA), also received Fast Track designation from the US Food and Drug Administration (FDA) due to the high prevalence and impact of untreated night vision issues.

With topline results expected in mid-2025, Pepose highlighted masked data showing 71% of participants reported complaints of severe night driving disturbances on a questionnaire. If successful, phentolamine ophthalmic solution could become the first FDA-approved treatment for post-refractive surgery patients with reduced mesopic vision and disabling photic symptoms.

“The LYNX-2 study is fully enrolled and and we're expecting topline results mid-2025, and then, depending on the outcome, we will be doing a second Phase 3 registration trial,” Pepose told 

. “Hopefully, we'll be able to offer something for our patients who have no label, drug options.”

Pepose reports a relevant disclosure with Opus Genetics.

Pepose JS, McDonald MB, Katz J, et al. Randomized, Controlled, Phase 3 Studies of Phentolamine Solution in Keratorefractive Patients with Low Mesopic Vision and Photic Complaints. Paper presented at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. April 25-28, 2025. Los Angeles, CA.

Videos

Trial data reveal phentolamine ophthalmic solution's potential to treat night vision disturbances post-keratorefractive surgery, addressing a critical unmet need.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

A new case series points to a high rate of continued Janus Kinase (JAK) inhibitor utilization and positive treatment outcomes among patients with 

 who are Black or African American, with over half of JAK inhibitor prescriptions having been covered via insurance.

This case series was led by such investigators as Megan M. Mukenge, an MD candidate from the department of dermatology at Wake Forest University School of Medicine. Mukenge and colleagues highlighted that recent analyses prior to this case series have suggested differing impacts of alopecia areata on various racial and ethnic groups, with greater disease burdens being observed among patients identifying as Black.

“Although JAK inhibitors (JAKi) have emerged as a promising treatment for [alopecia areata], the response of Black patients to these therapies remains understudied, with Black and Hispanic/Latino patients generally underrepresented in trials,” Mukenge and colleagues wrote. “This study aimed to investigate the experience and response of Black patients with [alopecia areata] receiving JAKi therapy.”

The investigative team assessed Black/African American patients using a retrospective case series, looking specifically at individuals in this patient population who had undergone treatment with JAKi for alopecia areata at a specialized hair clinic within an academic dermatology department in the period between 2018 - 2024.

Various demographic data were collected by Mukenge and colleagues on these individuals, along with clinical information such as Severity of Alopecia Tool (SALT) scores. They evaluated statistical significance through the use of the Wilcoxon signed-rank test with continuity correction and the unpaired t-test.

There were 16 individuals evaluated in this case series, with 14 women and 2 men specifically. These patients had an average age of 29.6 years. The investigative team revealed that mean SALT scores of these patients had dipped from 66.7% before initiating JAKi therapy to 46.6% over the course of treatment.

This decline in SALT scores corresponded to an average reduction of 20.1% (

 = .045). There was an average treatment duration of 21.4 months among the study's subjects, with the most commonly-prescribed JAK inhibitor being baricitinib (56%).

Ritlecitinib was the next most-used JAKi, among 31%, followed by tofacitinib among 13% of those evaluated in the case series. Utilization of adjunctive medications was observed in 56% of the patients assessed in the study, while 44% received a JAKi as a monotherapy.

Regarding access to JAK inhibitor medications, 69% were found by the research team to be able to obtain their treatments through insurance with prior authorization. 31% of subjects could access medications using manufacturer-sponsored patient assistance programs.

A statistically significant difference in SALT score changes was not observed by the investigators with the addition of adjunctive treatments (

 > .05). Clinically, improvements related to regrowth in hair were seen in 63% of subjects. However, 12% remained stable and 19% would be classified by the investigative team as having been treatment refractory. Among those in the refractory case group, 2 individuals had trialed multiple JAK inhibitors. By the time of data collection, 15 individuals remained with JAKi therapy.

One of these individuals discontinued as a result of adverse effects, specifically nausea and severe headache. 

Overall, the retrospective case series underscores the outcomes of treatment usinf JAKi among patients with alopecia areata who identify as Black. The predominance of female participants was noted by the team as reflecting the greater prevalence of alopecia areata observed in women.

Both of the most commonly-implemented JAK inhibitors in this analysis were noted as having been approved by the 

 for alopecia areata therapy in adults. Ritlecitinib is also approved by the FDA for adolescents.

The positive results observed by Mukenge et al. in terms of SALT scores suggest that JAK inhibitors are effective in scalp involvement reductions among those with alopecia areata. A minority had not responded to JAKi, a finding potentially linked to longstanding disease duration (over 15 years) and extensive scalp involvement at the time of medication initiation.

The investigators further highlight that those without insurance coverage may require manufacturer assistance programs, a program they noted promotes greater equity. The case series's results highlight a high rate of ongoing JAKi use and favorable treatment outcomes, supporting the use of JAK inhibitors as an important therapeutic option among Black patients with this hair loss condition.

“Future studies may explore variations in cytokines and signaling pathways between different racial groups, as well as responses across different hair loss patterns,” they wrote.

 “These future directions will provide clinicians with valuable insights to guide early intervention and treatment decisions.”

Mukenge MM, Rao S, Obeime I. Larrondo, et al (2025). JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series. Int J Dermatol. 

O Ezemma, S Devjani, B Jothishankar, et al. “Racial and Ethnic Diversity in Janus Kinase Inhibitor Alopecia Areata Clinical Trials: A Systematic Review,” Skin Appendage Disorders 9, no. 5 (2023): 351–354, 

A recent case series highlights the efficacy of Janus Kinase (JAK) inhibitors in treating alopecia areata among Black or African American patients, with a significant portion of prescriptions covered by insurance. The study, led by Megan M. Mukenge and colleagues, involved 16 patients and demonstrated a notable reduction in Severity of Alopecia Tool (SALT) scores, indicating positive treatment outcomes. The most commonly used JAK inhibitors were baricitinib and ritlecitinib. The findings emphasize the importance of JAK inhibitors as a therapeutic option for this demographic, despite some patients remaining treatment refractory.

These data were the conclusion of a case series highlighting the experiences and responses of African American patients with alopecia areata who utilize JAK inhibitors.

Alopecia

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Experiences with JAK Inhibitors Highlighted Among Black Patients with Alopecia Areata

TEV ‘749 Survey Shows Many Nurses Prefer Intramuscular Injections, with Andrew Cutler, MD

Teva Pharmaceuticals announced new TEV- ‘749 data on March 31, 2025, finding that more than 90% of patients, 87% of nurses, and 73% of physicians reported satisfaction about the initiation regimen, monthly dosing schedule, and dosing options of this once-monthly subcutaneous olanzapine long-acting injectable (LAI) for schizophrenia.

The survey was conducted via the phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS), an 8-week, randomized (1:1:1), double-blind, placebo-controlled trial evaluating TEV- ‘749. These findings followed other promising SOLARIS data, including the statistically significant mean differences in the Positive and Negative Syndrome Scale (PANSS) total score from baseline, as well as the improvements in social functioning and quality of life.

HCPLive spoke with SOLARIS investigator Andrew J. Cutler, MD, clinical associate professor of psychiatry at SUNY Upstate Medical University and chief medical officer at Neuroscience Education Institute, about Teva’s prospective, cross-sectional, observational, online study completed by 70 patients, 11 physicians, and 24 nurses who reported their attitudes on and experiences with LAI treatment, delivery of care, and treatment satisfaction. Cutler discussed the drivers behind the 

, unexpected findings, and what are the next steps for advancing TEV- ‘749 toward regulatory approval.

“One of the things that was a little surprising was there were some of the doctors and some of the nurses who actually didn't prefer subcutaneous—they felt more comfortable with an intramuscular injection,” Cutler said. “Some of that is simply their familiarity with intramuscular. They trust it. They know it can work, and they maybe haven't quite yet had enough experience with a subcutaneous delivery to trust it and to feel it was going to be as effective.”

The survey revealed 50% and 45.5% of nurses and physicians preferred intramuscular injections, respectively, opposed to most patients preferring a subcutaneous injection (78.6%).

Cutler explained how certain patient populations may benefit the most from TEV- ‘749, including those who do not adhere to their current treatments. Often, LAIs are not offered to patients until later in their treatment regimen, after they have had multiple relapses. However, as Cutler said, frequent relapses damage the brain and decrease function; Cutler suggests offering these patients LAIs after failing to adhere to 1 or 2 oral medications.

He said the steps for research is studying long-term safety in a certain number of patients to prove TEV- ‘749 is not associated with a risk of Post-Injection Delirium/Sedation Syndrome (PDSS). Cutler added that, until the discovery of new mechanisms of action, the most effective way to maximize an anti-psychotic class’s potential is to use an LAI.

“Sometimes you haven't seen the magic of an LAI until you've seen a consistent therapeutic blood level over time, and the really best way—maybe only way to deliver that—is through a long-acting injection,” Cutler said. “I think we have a lot of work to do on convincing clinicians of the value of LAIs to and overcome some of the barriers to LAI usage, which can include all kinds of things like the formulation, the initiation regimen… [and] some systemic issues.”

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable. Teva. March 31, 2025. 

https://www.tevausa.com/news-and-media/press-releases/new-data-strengthens-tevas-schizophrenia-portfolio-including-phase-3-solaris-trial-survey-results-demon/

Derman, C. Phase 3 Data Shows TEV-‘749 Injection Improves Social Function in Schizophrenia. HCPLive. November 6, 2024. 

https://www.hcplive.com/view/phase-3-data-shows-tev--749-injection-improves-social-function-in-schizophrenia

Derman, C. TEV- ‘749 Once-Monthly LAI Yields High Satisfaction in Phase 3 Trial, with Andrew J. Cutler, MD. HCPLive. April 21, 2025. 

https://www.hcplive.com/view/tev--749-once-monthly-lai-yields-high-satisfaction-in-phase-3-trial-with-andrew-j-cutler-md

Teva Pharmaceuticals' TEV-‘749, a once-monthly subcutaneous olanzapine long-acting injectable (LAI) for schizophrenia, demonstrated high satisfaction among patients, nurses, and physicians in the phase 3 SOLARIS trial. Despite some healthcare professionals' preference for intramuscular injections, patients favored subcutaneous delivery. The study highlighted the potential benefits of LAIs for patients with adherence issues, suggesting earlier intervention could prevent relapses. Future research will focus on long-term safety and addressing barriers to LAI adoption, emphasizing the importance of consistent therapeutic blood levels for maximizing antipsychotic efficacy.

Cutler told HCPLive it was surprising that a new survey on subcutaneous TEV- ‘749 revealed 50% and 45.5% of nurses and physicians, respectively, preferred intramuscular injections.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Norouzi discusses recent advancements in IgAN therapeutics and looks ahead to a potential first FDA-approved FSGS treatment.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

The Evolving IgAN Treatment Landscape and Advances in FSGS, with Sayna Norouzi, MD

3-year interim analysis of the SERENA study confirmed the safety of secukinumab to treat psoriatic arthritis and ankylosing spondylitis.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Spondyloarthritis

The HCPLive spondyloarthritis page is a resource for medical news and expert insights on spondylitis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for autoimmune disease, and more.

Secukinumab Retention, Efficacy, Safety Confirmed by Recent Interim Analysis

Pegloticase treatment significantly improves serum urate levels and quality of life in kidney transplant recipients with gout, showing promising clinical benefits.

Gout

On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.

Pegloticase Managed Gout, Improved QoL Measures in Kidney Transplant Recipients

These preliminary findings on psilocybin-assisted therapy (PAT) for patients with fibromyalgia point to its potential, though additional large-scale research is needed.

Psilocybin-Assisted Therapy Well-Tolerated in Patients with Fibromyalgia

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Somatization syndromes and childhood trauma emerged as key predictors of fibromyalgia over rheumatoid arthritis in a recent study comparing both groups.

Somatization Syndrome, Childhood Trauma Identified as Fibromyalgia Predictors

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Findings suggest MetS is linked to greater levels of pain catastrophizing in psoriatic arthritis, highlighting the need for multidisciplinary care.

Metabolic Syndrome Worsens Pain Catastrophizing in Psoriatic Arthritis

Tumor necrosis factor-α inhibitors are suggested as the optimal treatment for both joint and skin symptoms.

TNF-α, IL-17A Inhibitors Achieve Superior Arthritis, Skin Responses in PsA

Recent research highlights low certainty in sleep interventions for fibromyalgia, yet exercise shows promise in improving sleep quality.

Exercise Training May Help Improve Sleep in People With Fibromyalgia

These findings point to a need for evidence-based digital health information access to counter misinformation regarding androgenetic alopecia.

Androgenetic Alopecia Strongly Impacts Psychological Well-Being of Male Patients

Ahmad Masri, MD, MS, is the director of the Hypertrophic Cardiomyopathy Center at Oregon Health and Science University. 

Panelists discuss how early clinical suspicion, genetic testing, cardiac biomarkers, and imaging techniques are crucial for diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM), while also highlighting challenges such as common misdiagnoses and delayed diagnoses, which can significantly impact patient outcomes and quality of life.

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Latest News

Self-Administered Etripamil Nasal Spray Treats Tachycardia, Study Suggests

People With Fibromyalgia Have Higher Rates of Astigmatism, Dry Eye, MGD

Phentolamine Ophthalmic Solution for Low Mesopic Vision, With Jay Pepose, MD, PhD

Experiences with JAK Inhibitors Highlighted Among Black Patients with Alopecia Areata

TEV ‘749 Survey Shows Many Nurses Prefer Intramuscular Injections, with Andrew Cutler, MD